Intratumoral checkpoint subversion as a strategy for minimizing adverse effects
暂无分享,去创建一个
Nina Bhardwaj | Sacha Gnjatic | Leah Alabanza | Joshua Brody | S. Gnjatic | N. Bhardwaj | J. Brody | Leah M. Alabanza
[1] A. Weinberg,et al. OX40-Mediated Memory T Cell Generation Is TNF Receptor-Associated Factor 2 Dependent 1 , 2003, The Journal of Immunology.
[2] C. Goodnow,et al. CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10–driven MARCH1-mediated ubiquitination and degradation , 2011, The Journal of experimental medicine.
[3] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[4] D. Bigner,et al. Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function , 2007, Clinical Cancer Research.
[5] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[6] D. Moss,et al. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720) , 1995, Journal of virology.
[7] J. Allison,et al. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.
[8] S. Rosenberg,et al. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.
[9] Wenda Gao,et al. OX40 costimulation turns off Foxp3+ Tregs. , 2007, Blood.
[10] Y. Liu,et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. , 2007, Cancer research.
[11] S. Sad,et al. Archaeosomes Induce Long-Term CD8+ Cytotoxic T Cell Response to Entrapped Soluble Protein by the Exogenous Cytosolic Pathway, in the Absence of CD4+ T Cell Help1 , 2000, The Journal of Immunology.
[12] C. Slingluff,et al. The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides , 2012, Journal of immunotherapy.
[13] L. Zitvogel,et al. CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab? , 2008, Clinical Cancer Research.
[14] D. Schadendorf,et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.
[15] Michael R. Green,et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. , 2013, The Journal of clinical investigation.
[16] H. Schneider,et al. CTLA-4 Activation of Phosphatidylinositol 3-Kinase (PI 3-K) and Protein Kinase B (PKB/AKT) Sustains T-Cell Anergy without Cell Death , 2008, PloS one.
[17] C. Melief,et al. Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects , 2013, Clinical Cancer Research.
[18] J. Yates,et al. Differential expression of CTLA‐4 among T cell subsets , 2004, Clinical and experimental immunology.
[19] L. Zitvogel,et al. Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.
[20] P. Sabbatini,et al. Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients , 2012, Clinical Cancer Research.
[21] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.